Work

Azacitidine combined with crenolanib abrogates niche protection and expansion of residual leukemic stem cells (LSC) in FLT3-ITD+ acute myeloid leukemia (AML) with concurrent gene mutations in NPM1, DNMT3A or TET2

Year: 2017
Type: dissertation
Abstract: Tyrosine kinase inhibitors (TKI) have limited impact as single agents in FLT3-ITD+ acute myeloid leukemia (AML), failing to eradicate leukemic stem cells (LSC) in the bone marrow. Using primary AML samples and a patient-derived xenograft model, we show that stromal resistance of FLT3-ITD+ LSC to TKI depends on co-existing epigenetic mutations. Combining the FLT3-selective TKI crenolanib with the hypomethylating agent azacitidine (AZA) abrogates stromal protection and survival of FLT3-ITD+ LSC.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W2773631349
Cites: 154
Cited by:
Related to: 10